期刊文献+

无细胞百白破b型流感嗜血杆菌联合疫苗安全性观察

Safety of Acellular Haemophilus Influenzae Type b Vaccine
下载PDF
导出
摘要 目的探讨无细胞百白破b型流感嗜血杆菌联合疫苗安全性观察。方法回顾性分析2018年1—11月在我院儿保科行疫苗接种的1299例儿童的临床资料,根据接种疫苗种类的不同分为两组,观察组使用无细胞百白破b型流感嗜血杆菌联合疫苗,对照组使用免费百白破疫苗,分析疫苗接种后11个月内不良反应发生情况。结果观察组发生3例轻微不良反应,对照组12例,发生率分别0.52%,1.67%,均属正常范围内。结论无细胞百白破b型流感嗜血杆菌联合疫苗整体安全性较高,不良反应发生率较低。 Objective To investigate the safety of acellular Haemophilus influenzae type b vaccine.Methods The clinical data of 1299 children vaccinated in the Department of Pediatrics from January to November 2018 were analyzed retrospectively.they were divided into two groups according to the different types of vaccinations.The observation group was treated with acellular Haemophilus influenzae type b vaccine,while the control group was treated with free break vaccine.The occurrence of adverse reactions within eleven months after vaccination was analyzed.Results 3 adverse reactions occurred in the observation group,but there were 12 cases in the control group,the incidence rate was 0.52%,1.67%,respectively,all was in the control.Conclusion The overall safety of acellular Haemophilus influenzae type b vaccine was higher and the incidence of adverse reactions was low.
作者 陈志丹 CHEN Zhidan(Vaccination Clinic,Zhuhai Maternal and Child Health Hospital,Zhuhai Guangdong 519000,China)
出处 《中国卫生标准管理》 2020年第16期40-42,共3页 China Health Standard Management
关键词 百日咳 白喉 破伤风 无细胞百白破b型流感嗜血杆菌 联合疫苗 安全性 不良反应 pertussis diphtheria tetanus acellular Haemophilus influenzae type b combined vaccine safety adverse reaction
  • 相关文献

参考文献12

二级参考文献63

  • 1陈扶持.接种百白破联合疫苗致血小板减少性紫癜1例[J].中国计划免疫,2005,11(6):509-509. 被引量:2
  • 2赵铠.新型联合疫苗──疫苗发展方向[J].中国生物制品学杂志,1996,9(4):184-187. 被引量:1
  • 3陈奕.疫苗安全性监测评价体系现状[J].浙江预防医学,2007,19(5):56-58. 被引量:7
  • 4卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[S].2010-06-03.
  • 5Ii RC, Li FX, Li YP, et 01. Immunogenicity and Safety of a DTaP-IPV /I PRP-T Combined Vaccine (Pentaxim? ) at 2,3,4 months or 3,4,5 months versus separate vaccines (DTaP, PRP-T and IPV) in healthy Chinese infants[C]. 13th Asian Pacific Congress of Pe?diatrics, Shanghai: 2009, Ah. E2142.
  • 6Li RC, u FX, u YP, et 01. Antibody persistence at 18-20 months of age following primary vaccination of healthy infants with a Combined DTaP-IPV /I PRP-T Vaccine (Pentaxim? ) com?pared to separate vaccines (DTaP, PRP- T, and IPV) and im munogenicity and safety of booster vaccination in the Peoples' Republic of China[C]. 5th Asian Congress of Pediatric Infectious Diseases. Taipei: 2010.
  • 7Lagos R, Kotloff K, Hoffenhach A, et 01. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vac?cine containing diphtheria, tetanus, acellular pertussis, inacti?vated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants[I]. Pediatr Infect DisJ, 1998, 17 (4): 294-304.
  • 8Capeding MR,Cadorna-CarlosJ. Book-Montellano M, et 01. Im?munogenicity and safety of a DTaP-IPV /I PRP approximately T combination vaccine given with hepatitis B vaccine: a randomized open-label trial[J]. Bull World Health Organ, 2008,86(6): 443-451.
  • 9Rodeghiero F, Stasi R, Gemsheimer T, et al. Standardization ofterminology, definitions and outcome criteria in immunethrombocytopenic purpura of adults and children: report from aninternational working group[ J]. Blood, 2009 , 113(11 ): 2386-2393.
  • 10Hsieh YL, Lin LH. Thrombocytopenic purpura following vaccina-tion in early childhood : experience of a medical center in the past2 decades[J]. J Chin Med Assoc, 2010, 73(12) : 634-637.

共引文献339

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部